Impact BioMedical (IBO) Acquires Celios
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Fox Factory sells Marucci Sports for $225M, cuts debt
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
Impact Biomedical Inc. Announces Acquisition of Celios®, “Protecting People, Plants, and Animals from the World’s Most Dangerous Pathogens With Clean-Room Air Quality”
February 26, 2025 8:30 AM ESTHOUSTON, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced the acquisition of Celios®, a pioneering air purification technology company, in a strategic, all equity transaction valued at approximately $1.15 million. This acquisition aligns with Impact Biomedicals focused roll-up strategy, expanding its portfolio with cutting-edge solutions that will generate immediate revenue while reinforcing its commitment to human health and wellness.
Celios® brings advanced air purification capability, featuring design, system, and method patents issued in the U.S. and other... More
